Abstract
Biological Approaches to Aggressive Cutaneous B-Cell Lymphomas.
Highlights
Specialty section: This article was submitted to Hematologic Malignancies, a section of the journal Frontiers in Oncology
The aggressive subtypes essentially include primary cutaneous diffuse large B-cell lymphoma leg type (PCDLBCL-LT) and intravascular large B-cell lymphoma (IVLBCL), both characterized by a poor outcome [2]
PCLBCL-LT preferentially involves the lower limb with rapidly growing tumors in elderly subjects, whereas IVLBCL is usually widely disseminated in extracutaneous sites at diagnosis, and the clinical appearance of cutaneous lesions may simulate inflammatory skin conditions [3]
Summary
Rituximab has been the first target therapy used in common clinical practice in B cell lymphomas. Associations with other MAbs targeting surface molecules different from CD20 in PCBCL have shown promising results To this regard a recent investigation has demonstrated the efficacy of a triple combination of rituximab, lenalidomide and the anti-PD1 inhibitor pembrolizumab in an elderly patient with refractory PCDLBCL-LT [15]. In order to improve increase CAR-T cell potency, the combination with immune checkpoint inhibitors could be a potential therapeutic strategy To this regard, a recent investigation has evaluated safety and efficacy of CD19-directed CAR T-cell therapy in combination with the PD-1 inhibitor nivolumab in patients with relapsed/refractory B-NHL [24]. A recent investigation has evaluated safety and efficacy of CD19-directed CAR T-cell therapy in combination with the PD-1 inhibitor nivolumab in patients with relapsed/refractory B-NHL [24] This therapeutic strategy might be a rational and worthwhile approach to treat PCDLBCL-LT
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
